Australia markets close in 4 hours 21 minutes

Island Pharmaceuticals Limited (ILA.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.05600.0000 (0.00%)
As of 10:50AM AEST. Market open.
Currency in AUD

Valuation measures4

Market cap (intra-day) 6.37M
Enterprise value 5.90M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)9.99
Enterprise value/revenue 533.61
Enterprise value/EBITDA -2.50

Trading information

Stock price history

Beta (5Y monthly) 0.32
52-week change 3-30.00%
S&P500 52-week change 322.38%
52-week high 30.1450
52-week low 30.0500
50-day moving average 30.0628
200-day moving average 30.0772

Share statistics

Avg vol (3-month) 3229.27k
Avg vol (10-day) 3397.02k
Shares outstanding 5113.8M
Implied shares outstanding 6113.8M
Float 832.59M
% held by insiders 158.74%
% held by institutions 12.43%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 June 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin -247.34%
Operating margin (ttm)-123.55%

Management effectiveness

Return on assets (ttm)-56.82%
Return on equity (ttm)-134.02%

Income statement

Revenue (ttm)960.12k
Revenue per share (ttm)0.01
Quarterly revenue growth (yoy)10,459.60%
Gross profit (ttm)N/A
EBITDA N/A
Net income avi to common (ttm)-2.37M
Diluted EPS (ttm)-0.0300
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)976.05k
Total cash per share (mrq)0.01
Total debt (mrq)507.83k
Total debt/equity (mrq)79.63%
Current ratio (mrq)1.57
Book value per share (mrq)0.01

Cash flow statement

Operating cash flow (ttm)-2.73M
Levered free cash flow (ttm)-2.02M